Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

Road Show Takeaways....

--2.6 million in the US diagnosed as opioid dependent. 1.1 million in treatment with methadone or buprenorphine.

--A lot of focus on Camurus injectables, Sheldon believes they will reach more patients than probuphine. Maybe, but in my opinion, but probuphine's higher price (for 6 months of treatment) may make them net out in terms of actual revenue. Plus, there is a discussion in their registration statement that patients may not opt for injection because once injected, it cannot be taken out (like probuphine can) e,g, if you need emergency surgery, it would prevent you from taking opioid based pain killers etc.

--No other buprenorphine implants are in development.

--The REMS, manufacturing complexities of the rods, clinical issues etc. make it much more difficult to enter the market post-patent expiration in 2024. What she described sounded nearly impossible, and well out of the reach of a typical tablet generic. So, we shouldn't worry about generics once the patent expires. Note that the license agreement continues for 15 years after patent expiration, and so TTNP basically has 23 years of royalties coming to them.

--Training of the sales force occurred the first week of January. Right now there are 70 reps out there selling probuphine.

--Side Note: Sheldon's words "with schizophrenia, the longer the treatment the better." In other words, what is needed is an implant like Braeburn is developing. I really wonder why TTNP is not moving to develop its own.